Current Report Filing (8-k)
January 04 2023 - 7:01AM
Edgar (US Regulatory)
0001279704
false
0001279704
2022-12-30
2022-12-30
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
December 30, 2022
Cellectar Biosciences, Inc.
(Exact Name of Registrant as Specified in its
Charter)
Delaware | |
1-36598 | |
04-3321804 |
(State or Other Jurisdiction of
Incorporation) | |
(Commission File Number) | |
(I.R.S. Employer Identification
Number) |
100
Campus Drive, Florham Park, NJ, 07932
(Address of Principal Executive Offices) (Zip
Code)
(608) 441-8120
(Registrant’s Telephone Number, Including
Area Code)
Not Applicable
(Former Name or Former Address, if Changed Since
Last Report)
Securities registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common Stock, par value $0.00001 per share |
|
CLRB |
|
NASDAQ |
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
¨
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended period for complying with any new or revised financial accounting standards provided pursuant to Section
13(a) of the Exchange Act. ¨
Item 1.01 Entry into a Material Definitive Agreement.
On December 30, 2022, Cellectar Biosciences, Inc. (the “Company”)
entered into an Amended Agreement of Lease (the “Amended Lease”), with CAMPUS 100 LLC (the “Landlord”).
Under the Amended Lease, the Company will continue to lease
3,983 square feet of rentable area on the second floor of a building located at 100 Campus Drive in Florham Park, New Jersey, commencing
on March 1, 2023 (the “New Commencement Date”) until April 30, 2029 (the “New Expiration Date). The Company also has
an option to extend the term of the Amended Lease for one additional 60-month period.
Under the terms of the Amended
Lease, the Company’s previously paid security deposit of $75,000 will be reduced to $23,566 and the aggregate rent due over
the term of the Amended Lease is approximately $918,000, which will be reduced to approximately $893,000 after certain rent
abatements. The Company will also be required to pay its proportionate share of certain operating expenses and real estate taxes
applicable to the leased premises.
The foregoing description of Amended Lease does not
purport to be complete and is subject to, and qualified in its entirety by reference to, the full text of the Lease, which will be
filed as an exhibit to the Company's Annual Report on Form 10-K.
Item 2.03 Creation of a Direct Financial Obligation or an Obligation
under an Off-Balance Sheet Arrangement of a Registrant.
The information set forth in Item 1.01 above is incorporated by reference
herein.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
CELLECTAR BIOSCIENCES, INC. |
|
|
|
Date: January 4, 2023 |
By: |
/s/ Chad J. Kolean |
|
Chad J. Kolean |
|
Chief Financial Officer |
Cellectar Biosciences (NASDAQ:CLRB)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cellectar Biosciences (NASDAQ:CLRB)
Historical Stock Chart
From Jul 2023 to Jul 2024